February 17, 2011
Cambridge, MA
Refresh your understanding of Federal Circuit case law in this program designed especially for IP lawyers practicing in biotechnology. Federal Circuit decisions can impact IP portfolio strategy on many levels and in significant or subtle ways. We have selected some decisions of particular importance that are worth a closer look.
Please join Finnegan attorneys Leslie A. McDonell and Amelia Feulner Baur, Ph.D., as they discuss the following biotechnology cases:
- Prometheus Laboratories Inc. v. Mayo Collaborative Services, et al.
- Method of treatment claims and 35 U.S.C. § 101
- Cancer Research Technology Ltd. v. Barr Laboratories, Inc.
- Prosecution latches and inequitable conduct
- Sun Pharmaceuticals Industries, Inc. v. Eli Lilly and Company
- Double patenting
Date:
Thursday, February 17, 2011
Time:
7:30 - 8:00 a.m.
Registration and Breakfast
8:00 - 9:00 a.m.
Program
Where:
Finnegan
55 Cambridge Parkway
Cambridge, MA
Articles
California Reaches Record $12.75 Million CCPA Settlement with General Motors Over Driver Data
June 4, 2026
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Federal Circuit IP Blog
When “and” and “e.g.” Matter: Federal Circuit Revives VLSI vs. Intel Case
May 14, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.